Perinatal EvidenceCompass
Prepopulated workbenchMED-253

Psychiatric adjuncts — hyperprolactinemia/NMS/catatonia

Bromocriptine

Nonpsychotropic or adjunctive use in medication adverse effects, catatonia, or NMS

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Bromocriptine
Entity type
single-ingredient drug
Active component(s)
Bromocriptine
Formulation / route / interval
Oral; formulation varies
Attachment entry
Bromocriptine
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Also: hyperprolactinemia and NMS
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

2 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

C-034Provisional public source

Accumulated early pregnancy experience with bromocriptine and cabergoline for prolactinoma has not shown a clear major adverse pattern, but psychiatric antipsychotic-induced hyperprolactinemia is a different indication and usually permits alternatives.

Public-source certainty descriptor
Moderate-low; accumulated observational series
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Periconception and early pregnancy
Comparator
Dopamine agonist exposure versus no exposure
Effect or numbers carried forward

No single causal estimate used

Limitations

Cabergoline exposure base is smaller; macroadenoma threat changes benefit-risk

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-035Provisional public source

Bromocriptine and cabergoline lower prolactin and can suppress milk production; routine postpartum suppression of physiologic lactation is not recommended in current labeling.

Public-source certainty descriptor
High pharmacologic and label certainty
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Early postpartum
Comparator
Dopamine agonist versus no suppression
Effect or numbers carried forward

No infant exposure estimate needed to establish lactation suppression

Limitations

A threatening macroadenoma may justify treatment despite feeding goals; postpartum vascular events underpin warnings

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending